Check out the latest features and columns!

Pharmaceutical Executive March 2023

March's Executive Profile features Davidek Herron, Global Head of Digital, Roche

The Pivot to Digital

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day

Focus and Fundamentals: CFO Strategies on the Journey to Commercialization

Pharm Exec's 18th Annual Pipeline Report focuses on spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics

Testing the Limits

 and can be reached at fpollaro@mjhlifesciences.com.

Podcasts

Fran Pollaro talks with Cathi Ahearn, senior vice president, worldwide commercial portfolio strategy, Bristol Myers Squibb about impediments and solutions to break down silos in order to get medications in the hands of patients faster.

Tearing Down Silos to Usher Innovative Medicines to Patients Faster

Articles

Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.



Biotech Companies Deal with Silicon Valley Bank Collapse

 and can be reached at mrivers@mjhlifesciences.com.

Judith Kulich, principal, patient health and equity lead, ZS, and Nan Gu, associate principal, patient health and equity, ZS, discuss health equity in pharma, specifically racial biases, and how the industry can address access and inequities going forward. 

Health Equity in Pharma: Q&A with ZS

Havas Health & You to navigate complexities around value, access, pricing, and reimbursement.

Havas Health & You Launches Dynamic Value and Access Consultancy, Archipelago

Pfizer will pay pay $229 a share in cash for the cancer specialist.

Pfizer Buys Seagen for $43 Billion to Strengthen Cancer Drug Access

Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.

Sanofi Agrees to Acquire Provention Bio For $2.9 billion

Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.

Sumitovant Biopharma Completes Acquisition of Myovant Sciences

Vice president of innovation ventures at IQVIA.

As the life sciences industry enters this next stage of growth, capitalizing on AI and digital transformation will be key to propelling innovation and ensuring that companies are prepared to tackle the challenges ahead.

Navigating Disruption in the Metapharma Era

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

Biopharma M&A: Year in Review, Ripples Ahead

 and can be reached at mhollan@mjhlifesciences.com.

The importance of not over-expanding during development, launch.

Featured Content

Pharmaceutical Executive March 2023

The Pivot to Digital

Focus and Fundamentals: CFO Strategies on the Journey to Commercialization

Testing the Limits